



REG Summit 2019 WORKING GROUP MEETING MINUTES: COPD

Meeting details	
Meeting location	Divani Palace Acropolis, Athens, Greece.
Meeting date	Thursday 28 th March
Meeting time	17:30
Chair(s)	Marc Miravittles
Attendees	Omar Usmani Joan Soriano Katia Verhamme Guilherme Safioti Alex Mushunje Ioanna Tsiligianni Alexander Mathioudakis Thomas Schuessler Sarah Lucas Despo Ierodiakonou Ron Dandurand Esther Metting Karen Mezzi Chin Kook Rhee Amanda Bracey Janwillem Kocks Alan Kaplan
Objectives	
1	Update on and next steps for current projects
2	New project ideas

Items	
Update and next steps for current projects	Validation of Control in COPD study Initial results from the study were presented – It was found using the restrictive criteria for control that controlled patients had fewer exacerbations than uncontrolled patients. The next steps for the analysis were presented- <ul style="list-style-type: none">- Evaluate the predictive value of the individual items of the control criteria- Test the modified criteria for control- Investigate the optimal criteria and cut-offs to define control- Test impact and stability criteria separately- Compare CAT, CCQ and symptoms as measures of control- Impact of the changes of control status during follow-up



	<p>Treatment types/changes in treatment will be looked at as a secondary outcome but will be difficult as there is lot of changes in drug treatment in both controlled and uncontrolled patients.</p> <p>Plan to finish analysis by the end of June and write up paper by the end of August.</p> <p>Aim is a tool to determine control that would ideally be used to assessed control at each appointment.</p> <hr/> <p>Real-life WISDOM -currently seeking funding, proposal is with BI. Next steps: REG will work with Helgo Magnussen to develop a more detailed protocol</p> <hr/> <p>FeNO in COPD - currently seeking funding. REG will begin discussing the development of a protocol with Marc Miravittles.</p>
<p>New projects</p>	<p>Full study into AATD</p> <p>Unclear whether funding would be possible in the UK given there is no licenced treatment, so may need to identify alternative populations.</p> <p>It was discussed that a lot of work on AATD was already completed in Spain. In the UK with OPCRD there is the opportunity to conduct a study with relatively large numbers of AATD patients.</p> <p>Need to consider approaching BSL and Grifols for funding.</p> <p>There are also other sources of AATD that could be considered in the future: In Sweden all patients go into a registry when diagnosed, may also be data from Ireland.</p>